middle.news
Syntara Doses First Patient in Pioneering Keloid Scar Trial
9:35am on Tuesday 15th of July, 2025 AEST
•
Healthcare
Read Story
Syntara Doses First Patient in Pioneering Keloid Scar Trial
9:35am on Tuesday 15th of July, 2025 AEST
Key Points
First patient dosed in Phase 1c SATELLITE trial for topical SNT-6302
Trial led by Professor Fiona Wood in partnership with University of Western Australia
Study focuses on safety, tolerability, and preliminary efficacy in active keloid scars
Next-generation agent SNT-9465 Phase 1 trial to start by end of July
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SYNTARA (ASX:SNT)
OPEN ARTICLE